Journal Article Review Ahead of print 1 citation
PubMed: 40830244 DOI: 10.1038/s41585-025-01077-9
Urinary bladder cancer needs more attention - recommendations for health care professionals and politicians in the European Union.
Nat Rev Urol
Authors: Thorsten H Ecke, Sarah Collen, Alex Filicevas, Theodoros Yfantis, Florence Le Calvez-Kelm, Bente Thoft Jensen, Hein van Poppel
Affiliations
- Department of Urology, Helios Hospital, Bad Saarow, Germany.
- Department of Urology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.
- European Association of Urology Policy Office, Arnhem, The Netherlands.
- European Association of Urology Policy Office, Arnhem, The Netherlands.
- World Bladder Cancer Patient Coalition, Brussels, Belgium.
- Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
- Department of Urology Aarhus University Hospital, Aarhus, Denmark.
- Department of Urology, KU Leuven, Leuven, Belgium.
Abstract
Cancer is a crucial health priority of the current European Commission and a pillar of a strong European Health Union. However, policy measures targeting cancer in the EU do not approach all types of cancer equally. Bladder cancer is the fifth most common cancer in Europe. Although bladder cancer is associated with one of the highest lifetime costs of any cancer, research funding is among the lowest. This imbalance has led to an alarming stagnation in the availability of diagnostic tools, which negatively affected the prognosis and treatment options for bladder cancer, and resulted in complex pathways for patients. The lack of bladder-cancer awareness drastically hinders early detection. Furthermore, insufficient understanding of gender differences in bladder-cancer symptoms exacerbates the gender gap, leading to worse outcomes for women. After the European elections in 2024 and the learnings from Europe's Beating Cancer Plan, additional effort is needed to inform the policymakers in Brussels and the Member-State capitals to consider an EU agenda with ambitious policy actions targeting neglected cancers, such as bladder cancer, and close the cancer-care gap by supporting awareness and education and by ensuring access to high-quality diagnostic tools, care and treatment.
MeSH
Urinary Bladder, Urinary Bladder Neoplasms, Neoplasms, Urologic Diseases, Therapeutics, European Union